Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Seaport Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Seaport Therapeutics, Inc.’s stock price such as:

• Seaport Therapeutics, Inc.’s current stock price and volume
• Why Seaport Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for SPTX from analysts
• SPTX’s stock price momentum as measured by its relative strength

About Seaport Therapeutics, Inc. (SPTX)

Before we jump into Seaport Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company’s lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.

Want to learn more about Seaport Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Seaport Therapeutics, Inc..

Seaport Therapeutics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Seaport Therapeutics, Inc.’s stock price was $20.460.

Seaport Therapeutics, Inc. is up 0.69% from its previous closing price of $20.320.

During the last market session, Seaport Therapeutics, Inc.’s stock traded between $19.710 and $21.000. Currently, there are approximately 2.46 million shares outstanding for Seaport Therapeutics, Inc..

Seaport Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Seaport Therapeutics, Inc. Stock Price History

Seaport Therapeutics, Inc.’s (SPTX) price is currently down 5.8% so far this month.

During the month of July, Seaport Therapeutics, Inc.’s stock price has reached a high of $22.530 and a low of $17.890.

Over the last year, Seaport Therapeutics, Inc. has hit prices as high as $23.000 and as low as $14.850.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Seaport Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of July 30, 2026, there were analysts who downgraded Seaport Therapeutics, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Seaport Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Seaport Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Seaport Therapeutics, Inc. (SPTX) by visiting AAII Stock Evaluator.

Relative Price Strength of Seaport Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Seaport Therapeutics, Inc. has a weighted four-quarter relative price strength of %, which translates to a Momentum Score of and is considered to be NA.

Want to learn more about how Seaport Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Seaport Therapeutics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Seaport Therapeutics, Inc.’s stock price is $20.460, which is up 0.69% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Seaport Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.